Unicycive Therapeutics, Inc.UNCYNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-0.7%
5Y CAGR+64.4%
Year-over-Year Change
Research and development spending
3Y CAGR
-0.7%/yr
vs +145.2%/yr prior
5Y CAGR
+64.4%/yr
Recent deceleration
Acceleration
-145.9pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
12x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $12.17M | -39.2% |
| 2024 | $20.01M | +55.1% |
| 2023 | $12.90M | +3.7% |
| 2022 | $12.44M | +104.5% |
| 2021 | $6.08M | +499.0% |
| 2020 | $1.01M | +27.7% |
| 2019 | $795000.00 | +131.1% |
| 2018 | $344000.00 | - |